Sign in

CIK 0001658551

  • Non-accelerated filer
  • Smaller reporting company

Amylyx Pharmaceuticals, Inc.

Sign in to watch
Ticker
AMLX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
464600503
Phone
+1 617-682-0917
Business address
55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE, MA, 02142
  1. 4/A Open-market buy 10% owner bought 263,158 shares at $19.00 ($5,000,002)
  2. 3/A Insider 3/A
  3. 4 Grant or award Chief Legal Officer acquired 41,000 shares (grant or award)
  4. 3 Insider Initial Statement of Ownership
  5. 4 Open-market buy 10% owner bought 263,158 shares at $19.00 ($5,000,002)
  6. 3 Insider Initial Statement of Ownership
  7. 3 Insider Initial Statement of Ownership
  8. 4 Open-market buy 10% owner bought 2,300,000 shares at $19.00 ($43,700,000)
  9. 3 Insider Initial Statement of Ownership
  10. 4 Open-market buy Director bought 3,947 shares at $19.00 ($74,993)
  11. 4 Open-market buy Director bought 6,578 shares at $19.00 ($124,982)
  12. 4 Grant or award Chief Medical Officer acquired 28,333 shares (grant or award)
  13. 4 Open-market buy Director bought 26,315 shares at $19.00 ($499,985)
  14. 4 Grant or award Co-Chief Executive Officer acquired 75,000 shares (grant or award)
  15. 4 Derivatives Options or other derivatives
  16. 4 Open-market buy Chief Commercial Officer bought 6,842 shares at $19.00 ($129,998)
  17. 4 Grant or award Chief Financial Officer acquired 31,667 shares (grant or award)
  18. 4 Grant or award Co-Chief Executive Officer acquired 75,000 shares (grant or award)
  19. 3 Insider Initial Statement of Ownership
  20. 3 Insider Initial Statement of Ownership

Page 10 of 11 · 207 filings